| Literature DB >> 29534044 |
Darija Cör1, Željko Knez2,3, Maša Knez Hrnčič4.
Abstract
Ganoderma lucidum (Reishi) is a popular medicinal mushroom and has been used in oriental medicine because of its promoting effects on health and life expectancy. G. lucidum contains various compounds with a high grade of biological activty, which increase the immunity and show antitumour, antimicrobial, anti-inflammatory, antioxidant and acetylcholinesterase inhibitory activity. Several of these substances belong to the triterpenoids and polysaccharides classes. Proteins, lipids, phenols, sterols, etc. are also present. In the present review, an extensive overview of the presence of antitumour, antimicrobial, antioxidant and antiacetylcholinesterase compounds in G. lucidum extracts will be given, along with an evaluation of their therapeutic effects.Entities:
Keywords: G. lucidum; biological activity; polyscaccharides; triterpenoids
Mesh:
Substances:
Year: 2018 PMID: 29534044 PMCID: PMC6017764 DOI: 10.3390/molecules23030649
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Ganoderma lucidum pharmacological effects related to the specific group of biological compounds [14].
Figure 2Distribution of publications per year from Scopus Database according to the keyword search: “Ganoderma lucidum pharmaceutical” [15].
Other substances of G. lucidum [22].
| Compound | Content [mg/100 g] |
|---|---|
| Calcium | 832 |
| Phosphorus | 4.150 |
| Iron | 82.6 |
| Magnesium | 1.030 |
| Sodium | 375 |
| Potassium | 3.590 |
| Vitamin B1 | 3.49 |
| Vitamin B2 | 17.10 |
| Vitamin B6 | 0.71 |
| Choline | 1.150 |
| Niacin | 61.9 |
| Inositol | 307 |
Figure 3Structural formulas of ganoderic acid and lucidenic acid [23].
Triterpenes isolated from G. lucidum.
| Triterpene | Tumour cells | Action | Molecular Structure | Target | Ref. | |
|---|---|---|---|---|---|---|
| Ganoderic acid (3α,22β-diacetoxy-7α-hydroxyl-5α-lanost-8,24- | in vitro | Lung:95D | cytotoxic | [ | ||
| Ganoderic acid Mk | in vitro | Lung:95D | cytotoxic | [ | ||
| Ganoderic acid S | Lung:95D | cytotoxic | [ | |||
| Ganoderic acid Mf | Lung:95D | cytotoxic | [ | |||
| Ganoderic acid R | Lung:95D | Cytotoxic | [ | |||
| Ganoderic acid Mc | Lung:95D | Cytotoxic | [ | |||
| Ganoderic acid A | Breast: MDA-MB-231 | Inhibited growth and invasive behaviour of breast cancer cells | AP-1 or NF-κB | [ | ||
| Ganoderic acid F | Breast: MDA-MB-231 | Ineffective | AP-1 NF-κB | [ | ||
| Ganoderic acid H | Breast: MDA-MB-231 | Inhibited growth and invasive behaviour of breast cancer cells | AP-1 NF-κB | [ | ||
| ganoderic acid X | in vitro | Liver: HuH-7 | Inhibits topoisomerases and induces apoptosis of cancer cells | ERK, JNK | [ | |
| ganoderic acid T | in vitro | lung: 95D | Decrease in proliferation of some cancer cells. Strongly inhibits the formation of cell colony of 95-D. | p53 Bax | [ | |
| in vitro | colon: HCT-116 | Inhibits proliferation | NFκB-α, MMP-9, uPA, iNOS | [ | ||
| in vitro | melanoma: A375 | Inhibits growth | MMP2/9 | [ | ||
| in vivo | Lung: LLC | Suppresses tumour growth and LLC metastasis | MMP 2/9 | [ | ||
| ganoderic acid Me | in vitro | Colon: HCT-116 | Possesses cytotoxicity | p53 | [ | |
| in vitro | Lung: 95-D | inhibits cancer cell invasion | MMP 2/9 | [ | ||
| in vitro | Breast: MDA-MB-231 | inhibits proliferation and invasion and induces apoptosis | NF-κB, TNF-α, VEGF, IL-6/8, MMP-9, Bcl-2, c-Myc and CCND1 | [ | ||
| ganoderic acid D | in vitro | Cervical: HeLa | inhibits proliferation | AHA1 | [ | |
| ganoderic acid E | in vitro | Liver: Hep G2 | cytotoxic | [ | ||
| ganoderic acid DM | in vitro | Prostate: PC-3, LnCaP | inhibits prostate cancer cell proliferation and metastasis | MMP-2 MMP-9 | [ | |
| lucidenic acid A | leukaemia: HL 60 | decreases cell population growth, cell cycle arrest | Bcl-2 | [ | ||
| lucidenic acid B | leukaemia: HL 60 | Induces apoptosis | Bcl-2 | [ | ||
| liver: HepG2 | MMP-9, NF-κB, ERK1/2, AP-1, | |||||
| lucidenic acid C | leukaemia: HL 60 | decreases cell population growth, cell cycle arrest | Bcl-2 | [ | ||
| lucidenic acid N | leukaemia: HL 60 | decreases cell population growth, cell cycle arrest | Bcl-2 | [ | ||
| Ganoderiol F | in vitro | Lung: LLC | Cytotoxicity | [ | ||
| in vivo | Lung: LLC | inhibitory effect on tumour growth | [ | |||
| Ganodermanontriol | Colon: HCT-116, HT-29 | Inhibition of cell proliferation | β-catenin, cyclin-D1, | [ | ||
| Breast: MDA-MB-231 | uPA, uPAR |